BioSpace News Archive

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the expansion of the company’s pipeline of small molecule candidates across a range of highly prevalent human diseases. These preclinical programs — AMPKβ2 (

CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”), today announced the completion of two business development initiatives. In the first, CRH completed an accretive transaction whereby the Company has acquired 75% of a gastroenterology (“GI”) anesthesia practice, Lake Lanier Ane

Takara Bio USA, Inc. (TBUSA), a pioneering life science instrument and reagent company and wholly owned subsidiary of Takara Bio Inc., collaborated with bioSyntagma, Inc. and their partners to develop and validate a new high-throughput method for detecting SARS-CoV-2. The method employs automation technology and reagents from TBUSA to detect viral RNA via real-time PCR and will enable rapid, large-scale testing of tho

Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced it is presenting a poster featuring a post-hoc analysis of a Phase 3 trial of children with ADHD comparing the optimized dose JORNAY PM ® (Methylphenidate HCl) to the study par

Builds on long-standing relationship and lays groundwork for next decade in patient care Partnership will make better health easier throughout Pennsylvania and in all communities that Geisinger serves Drive digital health collaborations, including artificial intelligence-enabled applications

Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and chronic diseases today announces the signing of a global license and development agreement with Vectura Group plc (LSE: VEC) (“Vectura”) to develop and commercialize inhaled imatinib for the treatment of Pulmonary Arterial Hypertension (“PAH”). Aerami will be responsible for the overall de

New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy — After Two Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels— — Majority of Patients Treated Daily Also Reported Lower Rates of Adverse Events and Showed Higher Rates of Desensitization Compared to Non-Daily Dosing Groups —

Cognition Therapeutics, Inc. , a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected to total $75.8 million over five years to support a 540-patient Phase 2 study of CT1812 in indi

Adaptation Health, in partnership with Acumen America and the Center for Health Care Strategies announce the selected companies and panelists to a 3-part virtual demo day series: Responding to COVID-19 and Beyond: Demo Day for Medicaid Innovation.

Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:20 p.m. ET (11:20 a.m. CT). Investors and other interested parties will be able to access a live audio webcast of the present